Glenmark Licenses APC's Antigen Presenting Cell-Based Anticancer Candidate

05:05 EDT 21 Jun 2017 | Genetic Engineering News

APC Therapeutics granted Glenmark Pharmaceuticals an exclusive license to a small-molecule anticancer compound based on APC's antigen-presenting cell technology. Glenmark said the compound could potentially be used as either monotherapy or in combination with approved treatments. The firm will shoulder all clinical development responsibilities, along with regulatory and commercialization activities worldwide. Financial details of the deal were not disclosed. "Glenmark is an ideal partner to advance such an important scientific breakthrough treatment to patients with cancer," commented Vinod Patel and Venkateshwar Reddy, cofounders of APC Therapeutics. "This partnership is strategically significant for APC Therapeutics as it validates and advances our commitment to bring the right immunotherapies to the right patient populations." Dr. Reddy has joined Glenmark as vice president and global head of translation sciences. The Boston, MA-based APC is a privately held biopharma company developing an immuno-oncology pipeline of small-molecule drugs with an antigen-presenting cell mechanism ...

Original Article: Glenmark Licenses APC's Antigen Presenting Cell-Based Anticancer Candidate


More From BioPortfolio on "Glenmark Licenses APC's Antigen Presenting Cell-Based Anticancer Candidate"

Quick Search


Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...